Vertex Pharmaceuticals VRTX Total debt

Total debt at other companies

Lexicon PharmaceuticalsLXRX

$57.71M-45.7%

Travere Therapeutics, Inc.TVTX

$15.58M-82.6%

Agios PharmaceuticalsAGIO

$31.17M-36.1%

AbbVieABBV

$62.36B+1.8%

4D Molecular TherapeuticsFDMT

$20.54M-13.9%

Beam TherapeuticsBEAM

$250.82M+58.6%

FAQ

What is Vertex Pharmaceuticals's total debt?

Vertex Pharmaceuticals (VRTX) reported total debt of $1.98B in Q2 2026.

How has Vertex Pharmaceuticals's total debt changed year-over-year?

Vertex Pharmaceuticals's total debt increased by 29.5% year-over-year, from $1.53B to $1.98B.

What is the long-term trend for Vertex Pharmaceuticals's total debt?

Over 5 years (2020 to 2025), Vertex Pharmaceuticals's total debt has grown at a 16.7% compound annual growth rate (CAGR), from $942.5M to $2.04B.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.